Industry & Investors

BioCurate is owned jointly by Monash University and the University of Melbourne, but is independently governed by a highly skilled Board. It brings the advanced commercialisation skills and funding needed to address successfully the early stage “valley of death” that faces new discoveries.  By doing so it unlocks the combined exceptional biomedical research strengths in Melbourne, enabling significant new discoveries to be translated more rapidly into new medicines; with potentially huge health and economic benefits to Victoria and Australia.
 
A wide range of drug candidates are currently at preclinical or early clinical stages at both Universities. The targeted diseases range from preeclampsia, a potentially fatal condition in pregnancy, to various forms of epilepsy and other devastating neurological diseases, severe kidney, lung and cardiovascular disorders as well as a range of cancers and infectious diseases. BioCurate
will enable some of these and other transformational drug candidates to become a medical and commercial reality, by combining expertise and scale of both partners.


Dr Andrew Cuthbertson BMedSci, MBBS, PhD, FTSE, FAHMS Chief Scientific Officer and R&D Director CSL Ltd

Dr Andrew Cuthbertson
BMedSci, MBBS, PhD, FTSE, FAHMS
Chief Scientific Officer and R&D Director
CSL Ltd

“People talk about multiple valleys of death in our biotech industry and the venture between Monash and Melbourne squarely addresses the first of these which is really to try to identify that handful of potentially valuable product candidates from the sea of basic science discoveries.”